Tango Therapeutics TNGX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tango Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tango Therapeutics's financing cash flow?
- Tango Therapeutics (TNGX) reported financing cash flow of $79.85M in Q1 2026.
- How has Tango Therapeutics's financing cash flow changed year-over-year?
- Tango Therapeutics's financing cash flow increased by 3992200.0% year-over-year, from $2K to $79.85M.
- What is the long-term trend for Tango Therapeutics's financing cash flow?
- Over 3 years (2022 to 2025), Tango Therapeutics's financing cash flow has grown at a 416.5% compound annual growth rate (CAGR), from $1.62M to $222.5M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.